Skip to main content
. 2023 Dec;9(4):33–38. doi: 10.22034/CMM.2024.345186.1502

Table 2.

Antifungal susceptibility of isolates in minimum inhibitory concentration (MIC (μg/mL))

Case no FLU VRC FC AMB CAS MFG Antifungal medication provided for the patient
1 SDD (4) R (2) R (≥64) R (2) S (0.25) S (0.12) The patient was discharged against medical advice; hence, no antifungal therapy was initiated on the patient.
2 R (8) R (1) R (≥64) R (8) S (0.25) S (≤0.06) No antifungal therapy was recommended as there was no evidence of infection.
3 R (32) R (1) R (≥64) R (8) S (0.25) S (≤0.06) No antifungal therapy was recommended as there was no evidence of infection.
4 R (8) R (2) R (≥64) R (2) S (0.25) S (0.12) The patient was discharged against medical advice; hence, no antifungal therapy was initiated on the patient.
5 R (16) R (2) R (≥64) R (8) S (0.25) S (0.12) No antifungal therapy was recommended as there was no evidence of infection.
6 R (32) R (2) R (≥64) S (0.5) S (0.25) S (0.12) The patient was started on injection of Caspofungin 50 mg (intravenous) OD with a loading dose of 70 mg IV, in view of candidemia. IV Caspofungin was provided for a total of 18 days.
7 R (32) R (2) R (≥64) R (8) S (0.25) S (0.12) The patient was started on injection of Caspofungin 50 mg (intravenous) OD with a loading dose of 70 mg IV, in view of candidemia. IV Caspofungin was given for a total of 11 days.

AMB: Amphotericin; CAS: Caspofungin; FC: Flucytosine; FLU: Fluconazole; MFG: Micafungin; MIC: Minimum inhibitory concentration; SDD: Susceptible-dose dependent; VRC: Voriconazole; OD: Once a day